Figure 5.
ChIP-PCR for MRTFA/SRF-regulated genes. Anti-SRF (A) and anti-MRTFA (B) binding at the indicated genes. On the basis of ChIP-seq results, the first 8 genes on the x-axes were predicted to have stronger SRF binding in the MRTFAOETPA+ group compared with the untreated group. The next 4 cytoskeletal genes were predicted to have SRF and MRTFA binding in multiple cell types. EGR3 (positive control) was predicted to have equal amounts of SRF binding under all conditions, and NANOG served as a negative control. (n = 3). Mean ± standard deviations. Asterisks represent significance with P ≤ .07.

ChIP-PCR for MRTFA/SRF-regulated genes. Anti-SRF (A) and anti-MRTFA (B) binding at the indicated genes. On the basis of ChIP-seq results, the first 8 genes on the x-axes were predicted to have stronger SRF binding in the MRTFAOETPA+ group compared with the untreated group. The next 4 cytoskeletal genes were predicted to have SRF and MRTFA binding in multiple cell types. EGR3 (positive control) was predicted to have equal amounts of SRF binding under all conditions, and NANOG served as a negative control. (n = 3). Mean ± standard deviations. Asterisks represent significance with P ≤ .07.

Close Modal

or Create an Account

Close Modal
Close Modal